[{"orgOrder":0,"company":"Delcath Systems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Delcath Systems \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Not Applicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hepatic Injection","sponsorNew":"Delcath Systems \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Delcath Systems \/ Not Applicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Melphalan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Melphalan Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Alkeran-Generic (melphalan hydrochloride) is a DNA alkylating agent of the bischloroethylamine type. It is approved for patients with multiple myeloma for whom oral therapy is not appropriate.

                          Brand Name : Alkeran-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 16, 2024

                          Lead Product(s) : Melphalan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The event will feature, updated Focus trial data and the role of Hepzato™ Kit (melphalan hydrochloride for injection/Hepatic Delivery System) as a potential treatment for patients with hepatic-dominant metastatic ocular melanoma.

                          Brand Name : Hepzato

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 05, 2021

                          Lead Product(s) : Melphalan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Delcath have reached the minimum endpoint target enrollment in the FOCUS trial and expects to announce top-line results around the middle of this year.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 13, 2020

                          Lead Product(s) : Melphalan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank